On December 3, 2020 Dr. Michael Spinner, from Stanford University, Department of Medicine, Division of Oncology, reported that it will present at the 2020 Virtual ASH (Free ASH Whitepaper) Annual Meeting an update to the recently published article in Blood Advances (Press release, Notable Labs, DEC 3, 2020, View Source [SID1234572228]). This study used Notable Labs’ fully automated ex vivo drug sensitivity screening platform to test living tumor biopsies from patients with MDS and related myeloid neoplasms, and to identify correlations between clinical and genomic features and ex vivo drug sensitivity. Titled Correlating Clinical and Genomic Features with Ex Vivo Drug Sensitivity in Patients with Myelodysplastic Syndromes and Related Myeloid Neoplasms, this follow-up analysis involved patients evaluated at Stanford MDS Center between 2016-2020 with a diagnosis of MDS, MDS/MPN, or secondary AML. Ex vivo drug sensitivity screening defined three distinct patient clusters with differential sensitivity to numerous drug classes. Specific mutations were associated with greater ex vivo sensitivity to specific drug classes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To hear more about this exciting study and more, visit the virtual poster hall on Monday, December 7th from 7:30 am-3:30 pm PST.

Our Notable team will be attending ASH (Free ASH Whitepaper) this year. Schedule a meeting with our team and learn more about Notable’s proprietary automated, high-throughput, high-content, ex-vivo functional screening platform using living tumor biopsies.